BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36877518)

  • 1. Assessment of a Peer Physician Coaching Partnership Between a Designated Cancer Center Genetics Service and a Community Cancer Network Hospital.
    Santos LG; Buzdnitskaya T; Rolf BA; Souza W; Sienko M; Ruiz-Bonilla JA; Shah B; Jewell P; Jensen L; Horike-Pyne M; Elrod JA; Crews J; Laurino M; Weeks KA; Dubard-Gault ME
    JAMA Netw Open; 2023 Mar; 6(3):e231723. PubMed ID: 36877518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996.
    J Clin Oncol; 1996 May; 14(5):1730-6; discussion 1737-40. PubMed ID: 8622094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.
    Nicolosi P; Ledet E; Yang S; Michalski S; Freschi B; O'Leary E; Esplin ED; Nussbaum RL; Sartor O
    JAMA Oncol; 2019 Apr; 5(4):523-528. PubMed ID: 30730552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice.
    Czekalski MA; Huziak RC; Durst AL; Taylor S; Mai PL
    JCO Precis Oncol; 2022 Jan; 6():e2100409. PubMed ID: 35025618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
    Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
    Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
    JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing Breast Cancer Risks to Improve Care for an Increased-Risk Population within Eastern North Carolina.
    Shelton CH; Bowen C; Guenther WC; Jordan B; Boehmer LM; Weldon CB; Trosman JR; Ruiz A
    N C Med J; 2022; 83(3):221-228. PubMed ID: 35504701
    [No Abstract]   [Full Text] [Related]  

  • 10. Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    Kukafka R; Pan S; Silverman T; Zhang T; Chung WK; Terry MB; Fleck E; Younge RG; Trivedi MS; McGuinness JE; He T; Dimond J; Crew KD
    JAMA Netw Open; 2022 Jul; 5(7):e2222092. PubMed ID: 35849397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologists' perspectives of telephone genetic counseling to facilitate germline BRCA1/2 testing for their patients with high-grade serous ovarian cancer.
    Hemming P; Kaur R; Meiser B; McKinley J; Young MA; James PA; Forrest LE
    J Community Genet; 2021 Jul; 12(3):449-457. PubMed ID: 33956303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy.
    Dudley B; Karloski E; Monzon FA; Singhi AD; Lincoln SE; Bahary N; Brand RE
    Cancer; 2018 Apr; 124(8):1691-1700. PubMed ID: 29360161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to National Comprehensive Cancer Network Guidelines for
    Bobbili P; Olufade T; DerSarkissian M; Shenolikar R; Yu H; Duh MS; Tung N
    Hered Cancer Clin Pract; 2020; 18():13. PubMed ID: 32518611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.
    Armstrong J; Toscano M; Kotchko N; Friedman S; Schwartz MD; Virgo KS; Lynch K; Andrews JE; Aguado Loi CX; Bauer JE; Casares C; Bourquardez Clark E; Kondoff MR; Molina AD; Abdollahian M; Walker G; Sutphen R
    JAMA Oncol; 2015 Dec; 1(9):1251-60. PubMed ID: 26426480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiative.
    O'Grady MA; Gitelson E; Swaby RF; Goldstein LJ; Sein E; Keeley P; Miller B; Li T; Weinstein A; Cohen SJ
    J Natl Compr Canc Netw; 2007 Oct; 5(9):875-82. PubMed ID: 17977500
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kansu B; Gardner J; Price-Tate R; Murch O; Murray A
    J Obstet Gynaecol; 2021 Aug; 41(6):962-965. PubMed ID: 33228436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer.
    Teppala S; Hodgkinson B; Hayes S; Scuffham P; Tuffaha H
    J Med Econ; 2023; 26(1):19-33. PubMed ID: 36426964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
    Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
    JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing.
    Greenberg S; Buys SS; Edwards SL; Espinel W; Fraser A; Gammon A; Hafen B; Herget KA; Kohlmann W; Roundy C; Sweeney C
    Cancer Med; 2019 Nov; 8(15):6789-6798. PubMed ID: 31531966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.